{"id":135,"date":"2024-11-08T07:08:22","date_gmt":"2024-11-08T07:08:22","guid":{"rendered":"https:\/\/admit:8890\/?page_id=135"},"modified":"2025-03-06T18:25:23","modified_gmt":"2025-03-06T18:25:23","slug":"equipo-old","status":"publish","type":"page","link":"https:\/\/admit-therapeutics.com\/es\/equipo-old\/","title":{"rendered":"Equipo [old]"},"content":{"rendered":"\n<h1 class=\"wp-block-heading\">Equipo<\/h1>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:33.33%\">\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"313\" height=\"313\" src=\"https:\/\/admit:8890\/wp-content\/uploads\/2024\/11\/ferran-1.jpg\" alt=\"\" class=\"wp-image-150\" srcset=\"https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/ferran-1.jpg 313w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/ferran-1-300x300.jpg 300w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/ferran-1-150x150.jpg 150w\" sizes=\"auto, (max-width: 313px) 100vw, 313px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-left\">Ferran Prat<\/h2>\n\n\n\n<p>Presidente del Consejo de Administraci\u00f3n<\/p>\n\n\n\n<ul class=\"wp-block-social-links is-layout-flex wp-block-social-links-is-layout-flex\"><li class=\"wp-social-link wp-social-link-linkedin  wp-block-social-link\"><a href=\"https:\/\/www.linkedin.com\/in\/ferran-prat-9104915\/\" class=\"wp-block-social-link-anchor\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" version=\"1.1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" aria-hidden=\"true\" focusable=\"false\"><path d=\"M19.7,3H4.3C3.582,3,3,3.582,3,4.3v15.4C3,20.418,3.582,21,4.3,21h15.4c0.718,0,1.3-0.582,1.3-1.3V4.3 C21,3.582,20.418,3,19.7,3z M8.339,18.338H5.667v-8.59h2.672V18.338z M7.004,8.574c-0.857,0-1.549-0.694-1.549-1.548 c0-0.855,0.691-1.548,1.549-1.548c0.854,0,1.547,0.694,1.547,1.548C8.551,7.881,7.858,8.574,7.004,8.574z M18.339,18.338h-2.669 v-4.177c0-0.996-0.017-2.278-1.387-2.278c-1.389,0-1.601,1.086-1.601,2.206v4.249h-2.667v-8.59h2.559v1.174h0.037 c0.356-0.675,1.227-1.387,2.526-1.387c2.703,0,3.203,1.779,3.203,4.092V18.338z\"><\/path><\/svg><span class=\"wp-block-social-link-label screen-reader-text\">LinkedIn<\/span><\/a><\/li><\/ul>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<h2 class=\"wp-block-heading\">Ferran Prat<\/h2>\n\n\n\n<h4 class=\"wp-block-heading\">Presidente del Consejo de Administraci\u00f3n<\/h4>\n\n\n\n<p>\u00c9l cuenta con m\u00e1s de 30 a\u00f1os de experiencia en la industria de Ciencias de la Vida, principalmente en Diagn\u00f3stico y Farma. Ha ocupado cargos como CEO, Vicepresidente Corporativo de Marketing, Alianzas Estrat\u00e9gicas y Desarrollo de Negocio, as\u00ed como Director Comercial y Director de Operaciones en varias empresas, como VITRO Group, Werfen, LETI Pharma, DAKO (una compa\u00f1\u00eda de Agilent Technologies) donde ha tenido responsabilidad global en toda la cadena de valor, principalmente en la sede central, pero tambi\u00e9n en las regiones de EMEA, Am\u00e9rica y Asia Pac\u00edfico, regiones donde ha residido.<\/p>\n\n\n\n<p>Ferran es lincenciado en Farmacia por la Universidad de Barcelona, M\u00e1ster en Marketing por EADA (Barcelona, Espa\u00f1a) y Master en Transformaci\u00f3n Digital por IESE (Barcelona Spain).<\/p>\n<\/div>\n<\/div>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:33.33%\">\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"313\" height=\"313\" src=\"https:\/\/admit:8890\/wp-content\/uploads\/2024\/11\/marta.jpg\" alt=\"\" class=\"wp-image-146\" srcset=\"https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/marta.jpg 313w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/marta-300x300.jpg 300w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/marta-150x150.jpg 150w\" sizes=\"auto, (max-width: 313px) 100vw, 313px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-left\">Marta Barrachina<\/h2>\n\n\n\n<p>CEO<br>CO-FUNDADORA<br>Miembro del Consejo de Administraci\u00f3n<\/p>\n\n\n\n<ul class=\"wp-block-social-links is-layout-flex wp-block-social-links-is-layout-flex\"><li class=\"wp-social-link wp-social-link-x  wp-block-social-link\"><a href=\"https:\/\/x.com\/ADmitTherapeut1\" class=\"wp-block-social-link-anchor\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" version=\"1.1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" aria-hidden=\"true\" focusable=\"false\"><path d=\"M13.982 10.622 20.54 3h-1.554l-5.693 6.618L8.745 3H3.5l6.876 10.007L3.5 21h1.554l6.012-6.989L15.868 21h5.245l-7.131-10.378Zm-2.128 2.474-.697-.997-5.543-7.93H8l4.474 6.4.697.996 5.815 8.318h-2.387l-4.745-6.787Z\" \/><\/svg><span class=\"wp-block-social-link-label screen-reader-text\">X<\/span><\/a><\/li>\n\n<li class=\"wp-social-link wp-social-link-linkedin  wp-block-social-link\"><a href=\"https:\/\/es.linkedin.com\/in\/marta-barrachina-61b78934\" class=\"wp-block-social-link-anchor\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" version=\"1.1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" aria-hidden=\"true\" focusable=\"false\"><path d=\"M19.7,3H4.3C3.582,3,3,3.582,3,4.3v15.4C3,20.418,3.582,21,4.3,21h15.4c0.718,0,1.3-0.582,1.3-1.3V4.3 C21,3.582,20.418,3,19.7,3z M8.339,18.338H5.667v-8.59h2.672V18.338z M7.004,8.574c-0.857,0-1.549-0.694-1.549-1.548 c0-0.855,0.691-1.548,1.549-1.548c0.854,0,1.547,0.694,1.547,1.548C8.551,7.881,7.858,8.574,7.004,8.574z M18.339,18.338h-2.669 v-4.177c0-0.996-0.017-2.278-1.387-2.278c-1.389,0-1.601,1.086-1.601,2.206v4.249h-2.667v-8.59h2.559v1.174h0.037 c0.356-0.675,1.227-1.387,2.526-1.387c2.703,0,3.203,1.779,3.203,4.092V18.338z\"><\/path><\/svg><span class=\"wp-block-social-link-label screen-reader-text\">LinkedIn<\/span><\/a><\/li><\/ul>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<h2 class=\"wp-block-heading\">Marta Barrachina<\/h2>\n\n\n\n<h4 class=\"wp-block-heading\">CEO<br>CO-FUNDADORA<br>Miembro del Consejo de Administraci\u00f3n<\/h4>\n\n\n\n<p>Marta Barrachina es Doctora en Bioqu\u00edmica (Universidad de Barcelona) y Executive MBA (Universidad La Salle-Ramon Llull). Investigadora principal en el Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge durante 17 a\u00f1os. Autora de numerosos art\u00edculos cient\u00edficos publicados en revistas internacionales relacionadas con enfermedades neurodegenerativas, e inventora de 9 patentes. Es miembro del Consejo Asesor Cient\u00edfico de la Alzheimer&#8217;s Drug Discovery Foundation (ADDF) desde enero de 2021. CEO de la compa\u00f1\u00eda desde su creaci\u00f3n a finales de 2017.<\/p>\n<\/div>\n<\/div>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:33.33%\">\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"313\" height=\"313\" src=\"https:\/\/admit:8890\/wp-content\/uploads\/2024\/11\/santiago.jpg\" alt=\"\" class=\"wp-image-149\" srcset=\"https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/santiago.jpg 313w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/santiago-300x300.jpg 300w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/santiago-150x150.jpg 150w\" sizes=\"auto, (max-width: 313px) 100vw, 313px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-left\">Santiago Lozano<\/h2>\n\n\n\n<p>Miembro del Consejo de Administraci\u00f3n<\/p>\n\n\n\n<ul class=\"wp-block-social-links is-layout-flex wp-block-social-links-is-layout-flex\"><li class=\"wp-social-link wp-social-link-linkedin  wp-block-social-link\"><a href=\"https:\/\/www.linkedin.com\/in\/giacomodesimone1983\/\" class=\"wp-block-social-link-anchor\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" version=\"1.1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" aria-hidden=\"true\" focusable=\"false\"><path d=\"M19.7,3H4.3C3.582,3,3,3.582,3,4.3v15.4C3,20.418,3.582,21,4.3,21h15.4c0.718,0,1.3-0.582,1.3-1.3V4.3 C21,3.582,20.418,3,19.7,3z M8.339,18.338H5.667v-8.59h2.672V18.338z M7.004,8.574c-0.857,0-1.549-0.694-1.549-1.548 c0-0.855,0.691-1.548,1.549-1.548c0.854,0,1.547,0.694,1.547,1.548C8.551,7.881,7.858,8.574,7.004,8.574z M18.339,18.338h-2.669 v-4.177c0-0.996-0.017-2.278-1.387-2.278c-1.389,0-1.601,1.086-1.601,2.206v4.249h-2.667v-8.59h2.559v1.174h0.037 c0.356-0.675,1.227-1.387,2.526-1.387c2.703,0,3.203,1.779,3.203,4.092V18.338z\"><\/path><\/svg><span class=\"wp-block-social-link-label screen-reader-text\">LinkedIn<\/span><\/a><\/li><\/ul>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<h2 class=\"wp-block-heading\">Santiago Lozano<\/h2>\n\n\n\n<h4 class=\"wp-block-heading\">Miembro del Consejo de Administraci\u00f3n<\/h4>\n\n\n\n<p>Licenciado en Econ\u00f3micas (Univ. Navarra 1996) y Master en Direcci\u00f3n Financiera (ESIC 2004). Es colaborador del Master de Ingenier\u00eda Biom\u00e9dica de la Universidad de Navarra y de diferentes organismos internacionales para la evaluaci\u00f3n de proyectos innovadores en fases iniciales, especialmente del sector salud. Acumula una larga experiencia profesional de cerca de 25 a\u00f1os, inicialmente en el \u00e1mbito industrial (automoci\u00f3n en ICER Breaks) y posteriormente en el sector financiero (mercado de capitales en Gesnavarra SGIIC) y durante m\u00e1s de 15 a\u00f1os vinculado al Venture Capital y a la transferencia de Tecnolog\u00eda como Director de Fondos en Clave Capital; promoviendo diferentes fondos de transferencia de tecnolog\u00eda y analizando e invirtiendo en empresas tecnol\u00f3gicas en primeras fases, especialmente en los \u00e1mbitos de salud e ingenier\u00eda. Actualmente -adem\u00e1s- es tambi\u00e9n miembro de 15 consejos de administraci\u00f3n y director de UN I+D+i Tech Transfer f.c.r. y Navarra Tech Transfer Fund f.c.r., especializados principalmente en salud e ingenier\u00eda.<\/p>\n<\/div>\n<\/div>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-columns col-reverse is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<h2 class=\"wp-block-heading\">Maite Fibla<\/h2>\n\n\n\n<h4 class=\"wp-block-heading\">Miembro del Consejo de Administraci\u00f3n<\/h4>\n\n\n\n<p>Maite Fibla es doctora en Econom\u00eda y cofundadora y socia directora de Ship2B Ventures, una firma de capital riesgo de impacto nacida a finales de 2020 que gestiona m\u00e1s de 50 millones de euros e invierte en startups de alto impacto social y medioambiental. En 2013 tambi\u00e9n cofund\u00f3 la Fundaci\u00f3n Ship2B, cuyo objetivo es impulsar la econom\u00eda de impacto. La fundaci\u00f3n ha acelerado m\u00e1s de 200 startups y ha invertido en varias de alto impacto.<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:33.33%\">\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"313\" height=\"313\" src=\"https:\/\/admit:8890\/wp-content\/uploads\/2024\/11\/maite.jpg\" alt=\"\" class=\"wp-image-145\" srcset=\"https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/maite.jpg 313w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/maite-300x300.jpg 300w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/maite-150x150.jpg 150w\" sizes=\"auto, (max-width: 313px) 100vw, 313px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-left\">Maite Fibla<\/h2>\n\n\n\n<p>Miembro del Consejo de Administraci\u00f3n<\/p>\n\n\n\n<ul class=\"wp-block-social-links is-layout-flex wp-block-social-links-is-layout-flex\"><li class=\"wp-social-link wp-social-link-linkedin  wp-block-social-link\"><a href=\"https:\/\/www.linkedin.com\/in\/maite-fibla-gasparin-04854826\/\" class=\"wp-block-social-link-anchor\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" version=\"1.1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" aria-hidden=\"true\" focusable=\"false\"><path d=\"M19.7,3H4.3C3.582,3,3,3.582,3,4.3v15.4C3,20.418,3.582,21,4.3,21h15.4c0.718,0,1.3-0.582,1.3-1.3V4.3 C21,3.582,20.418,3,19.7,3z M8.339,18.338H5.667v-8.59h2.672V18.338z M7.004,8.574c-0.857,0-1.549-0.694-1.549-1.548 c0-0.855,0.691-1.548,1.549-1.548c0.854,0,1.547,0.694,1.547,1.548C8.551,7.881,7.858,8.574,7.004,8.574z M18.339,18.338h-2.669 v-4.177c0-0.996-0.017-2.278-1.387-2.278c-1.389,0-1.601,1.086-1.601,2.206v4.249h-2.667v-8.59h2.559v1.174h0.037 c0.356-0.675,1.227-1.387,2.526-1.387c2.703,0,3.203,1.779,3.203,4.092V18.338z\"><\/path><\/svg><span class=\"wp-block-social-link-label screen-reader-text\">LinkedIn<\/span><\/a><\/li><\/ul>\n<\/div>\n<\/div>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-columns col-reverse is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<h2 class=\"wp-block-heading\">Howard Fillit<\/h2>\n\n\n\n<h4 class=\"wp-block-heading\">Observador de la ADDF en el Consejo de Administraci\u00f3n<\/h4>\n\n\n\n<p>Howard Fillit es geriatra, neurocient\u00edfico y uno de los principales expertos en la enfermedad de Alzheimer y otras demencias relacionadas, y ha recibido numerosos premios y distinciones, entre ellos el Rita Hayworth Award de la Alzheimer&#8217;s Association. Es cofundador, director ejecutivo y director cient\u00edfico de la Alzheimer&#8217;s Drug Discovery Foundation (ADDF), una organizaci\u00f3n sin \u00e1nimo de lucro que ayud\u00f3 a crear en 1998. Es miembro de la Sociedad Americana de Geriatr\u00eda, el Colegio Americano de M\u00e9dicos, la Sociedad Gerontol\u00f3gica de Am\u00e9rica y la Academia de Medicina de Nueva York.<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:33.33%\">\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"313\" height=\"313\" src=\"https:\/\/admit:8890\/wp-content\/uploads\/2024\/11\/howard.jpg\" alt=\"\" class=\"wp-image-142\" srcset=\"https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/howard.jpg 313w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/howard-300x300.jpg 300w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/howard-150x150.jpg 150w\" sizes=\"auto, (max-width: 313px) 100vw, 313px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-left\">Howard Fillit<\/h2>\n\n\n\n<p>Observador de la ADDF en el Consejo de Administraci\u00f3n<\/p>\n\n\n\n<ul class=\"wp-block-social-links is-layout-flex wp-block-social-links-is-layout-flex\"><li class=\"wp-social-link wp-social-link-linkedin  wp-block-social-link\"><a href=\"https:\/\/www.linkedin.com\/in\/hfillit\/\" class=\"wp-block-social-link-anchor\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" version=\"1.1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" aria-hidden=\"true\" focusable=\"false\"><path d=\"M19.7,3H4.3C3.582,3,3,3.582,3,4.3v15.4C3,20.418,3.582,21,4.3,21h15.4c0.718,0,1.3-0.582,1.3-1.3V4.3 C21,3.582,20.418,3,19.7,3z M8.339,18.338H5.667v-8.59h2.672V18.338z M7.004,8.574c-0.857,0-1.549-0.694-1.549-1.548 c0-0.855,0.691-1.548,1.549-1.548c0.854,0,1.547,0.694,1.547,1.548C8.551,7.881,7.858,8.574,7.004,8.574z M18.339,18.338h-2.669 v-4.177c0-0.996-0.017-2.278-1.387-2.278c-1.389,0-1.601,1.086-1.601,2.206v4.249h-2.667v-8.59h2.559v1.174h0.037 c0.356-0.675,1.227-1.387,2.526-1.387c2.703,0,3.203,1.779,3.203,4.092V18.338z\"><\/path><\/svg><span class=\"wp-block-social-link-label screen-reader-text\">LinkedIn<\/span><\/a><\/li><\/ul>\n<\/div>\n<\/div>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-columns col-reverse is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<h2 class=\"wp-block-heading\">Russell Swerdlow<\/h2>\n\n\n\n<h4 class=\"wp-block-heading\">Asesor cient\u00edfico<\/h4>\n\n\n\n<p>El Dr. Russell Swerdlow es profesor en el Departamento de Neurolog\u00eda, Biolog\u00eda Celular y Fisiolog\u00eda, y Bioqu\u00edmica y Biolog\u00eda Molecular en la Facultad de Medicina de la Universidad de Kansas. Dirige el Centro de Investigaci\u00f3n en la enfermedad de Alzheimer de la Universidad de Kansas, su programa de Enfermedades Neurodegenerativas y la Medicina Mitocondrial del Centro Heartland. Se gradu\u00f3 en la Universidad de Nueva York y como neur\u00f3logo se especializ\u00f3 en Alzheimer en la Universidad de Virginia. Ocupa la c\u00e1tedra Gene and Marge Sweeney en la Universidad de Kansas y ha recibido prestigiosos premios, entre ellos el S. Weir Mitchell Award de la Academia Americana de Neurolog\u00eda, el Cotzias Award de la Asociaci\u00f3n Americana de la enfermedad de Parkinson, el Chancellor\u2019s Club Research Award de la Universidad de Kansas, el Dolph Simons Research Achievement Award en las Ciencias Biom\u00e9dicas de la Universidad de Kansas, y el Oskar Fischer Prize. Entre 2017-2021 ocup\u00f3 el Consejo asesor cient\u00edfico del NIA. La investigaci\u00f3n del Dr. Swerdlow est\u00e1 centrada en el metabolismo energ\u00e9tico cerebral, su papel en la enfermedad de Alzheimer, y su manipulaci\u00f3n terap\u00e9utica.<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:33.33%\">\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"313\" height=\"313\" src=\"https:\/\/admit:8890\/wp-content\/uploads\/2024\/11\/rusell.jpg\" alt=\"\" class=\"wp-image-148\" srcset=\"https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/rusell.jpg 313w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/rusell-300x300.jpg 300w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/rusell-150x150.jpg 150w\" sizes=\"auto, (max-width: 313px) 100vw, 313px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-left\">Russell Swerdlow<\/h2>\n\n\n\n<p>Asesor cient\u00edfico<\/p>\n\n\n\n<ul class=\"wp-block-social-links is-layout-flex wp-block-social-links-is-layout-flex\"><\/ul>\n<\/div>\n<\/div>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:33.33%\">\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"313\" height=\"313\" src=\"https:\/\/admit:8890\/wp-content\/uploads\/2024\/11\/courosh.jpg\" alt=\"\" class=\"wp-image-140\" srcset=\"https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/courosh.jpg 313w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/courosh-300x300.jpg 300w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/courosh-150x150.jpg 150w\" sizes=\"auto, (max-width: 313px) 100vw, 313px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-left\">Courosh Mehanian<\/h2>\n\n\n\n<p>Asesor cient\u00edfico<\/p>\n\n\n\n<ul class=\"wp-block-social-links is-layout-flex wp-block-social-links-is-layout-flex\"><li class=\"wp-social-link wp-social-link-linkedin  wp-block-social-link\"><a href=\"https:\/\/www.linkedin.com\/in\/courosh\/\" class=\"wp-block-social-link-anchor\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" version=\"1.1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" aria-hidden=\"true\" focusable=\"false\"><path d=\"M19.7,3H4.3C3.582,3,3,3.582,3,4.3v15.4C3,20.418,3.582,21,4.3,21h15.4c0.718,0,1.3-0.582,1.3-1.3V4.3 C21,3.582,20.418,3,19.7,3z M8.339,18.338H5.667v-8.59h2.672V18.338z M7.004,8.574c-0.857,0-1.549-0.694-1.549-1.548 c0-0.855,0.691-1.548,1.549-1.548c0.854,0,1.547,0.694,1.547,1.548C8.551,7.881,7.858,8.574,7.004,8.574z M18.339,18.338h-2.669 v-4.177c0-0.996-0.017-2.278-1.387-2.278c-1.389,0-1.601,1.086-1.601,2.206v4.249h-2.667v-8.59h2.559v1.174h0.037 c0.356-0.675,1.227-1.387,2.526-1.387c2.703,0,3.203,1.779,3.203,4.092V18.338z\"><\/path><\/svg><span class=\"wp-block-social-link-label screen-reader-text\">LinkedIn<\/span><\/a><\/li><\/ul>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<h2 class=\"wp-block-heading\">Courosh Mehanian<\/h2>\n\n\n\n<h4 class=\"wp-block-heading\">Asesor cient\u00edfico<\/h4>\n\n\n\n<p>Research Associate Professor, Affiliate Faculty<br>Knight Campus for Accelerating Scientific Impact, University of Oregon<br>Eugene, Oregon, USA<\/p>\n\n\n\n<p>Research Associate Professor, Affiliate Faculty<br>Oregon Health and Science University<br>Portland, Oregon, USA<\/p>\n\n\n\n<p>Principal Research Scientist, Machine Learning<br>Global Health Labs<br>Bellevue, Washington, USA<\/p>\n<\/div>\n<\/div>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:33.33%\">\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"313\" height=\"313\" src=\"https:\/\/admit:8890\/wp-content\/uploads\/2024\/11\/carlos.jpg\" alt=\"\" class=\"wp-image-139\" srcset=\"https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/carlos.jpg 313w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/carlos-300x300.jpg 300w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/carlos-150x150.jpg 150w\" sizes=\"auto, (max-width: 313px) 100vw, 313px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-left\">Carlos Cruchaga<\/h2>\n\n\n\n<p>Asesor cient\u00edfico<\/p>\n\n\n\n<ul class=\"wp-block-social-links is-layout-flex wp-block-social-links-is-layout-flex\"><\/ul>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<h2 class=\"wp-block-heading\">Carlos Cruchaga<\/h2>\n\n\n\n<h4 class=\"wp-block-heading\">Asesor cient\u00edfico<\/h4>\n\n\n\n<p>El Dr. Carlos Cruchaga es genetista humano experto en multi\u00f3mica, inform\u00e1tica y neurodegeneraci\u00f3n. Se doctor\u00f3 en Bioqu\u00edmica y Biolog\u00eda Molecular en 2005 en la Universidad de Navarra (Espa\u00f1a). Durante su primer posdoctorado realiz\u00f3 estudios estad\u00edsticos de gen\u00e9tica humana centrados en la enfermedad de Alzheimer y la enfermedad de Parkinson, completando su formaci\u00f3n en gen\u00f3mica humana cuantitativa. El Dr. Cruchaga estableci\u00f3 su laboratorio en la Universidad de Washington en 2011, estudiando la arquitectura gen\u00e9tica de las enfermedades neurodegenerativas. Sus intereses se centran en el uso de datos gen\u00f3micos humanos y otros datos \u00f3micos (prote\u00f3mica, metabol\u00f3mica, lipid\u00f3mica) para identificar y comprender el proceso biol\u00f3gico implicado en la enfermedad de Alzheimer, la enfermedad de Parkinson, la demencia frontotemporal y otros procesos neurodegenerativos. En 2019, se convirti\u00f3 en el l\u00edder del grupo de Neurogen\u00f3mica e Inform\u00e1tica de la Universidad de Washington.<br><\/p>\n<\/div>\n<\/div>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:33.33%\">\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"313\" height=\"313\" src=\"https:\/\/admit:8890\/wp-content\/uploads\/2024\/11\/jordi.jpg\" alt=\"\" class=\"wp-image-143\" srcset=\"https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/jordi.jpg 313w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/jordi-300x300.jpg 300w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/jordi-150x150.jpg 150w\" sizes=\"auto, (max-width: 313px) 100vw, 313px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-left\">Jordi Gasc\u00f3n<\/h2>\n\n\n\n<p>Asesor m\u00e9dico<br>CO-FUNDADOR<\/p>\n\n\n\n<ul class=\"wp-block-social-links is-layout-flex wp-block-social-links-is-layout-flex\"><\/ul>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<h2 class=\"wp-block-heading\">Jordi Gasc\u00f3n<\/h2>\n\n\n\n<h4 class=\"wp-block-heading\">Asesor m\u00e9dico<br>CO-FUNDADOR<\/h4>\n\n\n\n<p>Jordi Gasc\u00f3n es el actual Jefe de la Unidad de Demencias Funcionales del Hospital Universitario de Bellvitge y Profesor Asociado de Ciencias Morfol\u00f3gicas de la Universidad Aut\u00f3noma de Barcelona. Su experiencia en el manejo y tratamiento del deterioro cognitivo leve y las demencias (como la enfermedad de Alzheimer, la demencia con cuerpos de Lewy, la demencia frontotemporal y la esclerosis lateral amiotr\u00f3fica con deterioro cognitivo o conductual) le ha convertido en consultor de referencia en su hospital y le ha permitido colaborar con varias compa\u00f1\u00edas farmac\u00e9uticas en numerosos ensayos cl\u00ednicos.<\/p>\n<\/div>\n<\/div>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-columns col-reverse is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<h2 class=\"wp-block-heading\">Ram\u00f3n Re\u00f1\u00e9<\/h2>\n\n\n\n<h4 class=\"wp-block-heading\">Asesor m\u00e9dico<br>CO-FUNDADOR<\/h4>\n\n\n\n<p>Ramon Re\u00f1\u00e9 ha sido Jefe de la Unidad de Demencias Funcionales del Hospital Universitario de Bellvitge hasta su jubilaci\u00f3n. Su amplia experiencia en el tratamiento de pacientes con deterioro cognitivo leve, demencia vascular, degeneraci\u00f3n frontotemporal y demencia con cuerpos de Lewy le ha permitido liderar m\u00e1s de una docena de ensayos cl\u00ednicos en colaboraci\u00f3n con las principales compa\u00f1\u00edas farmac\u00e9uticas, como Grifols, Lundbeck, Astra Zeneca, Eli Lilly, Biogen y Roche. Adem\u00e1s, tambi\u00e9n se ha centrado en los cuidadores, manteniendo estrechos v\u00ednculos con asociaciones familiares de Alzheimer.<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:33.33%\">\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"313\" height=\"313\" src=\"https:\/\/admit:8890\/wp-content\/uploads\/2024\/11\/ramon.jpg\" alt=\"\" class=\"wp-image-147\" srcset=\"https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/ramon.jpg 313w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/ramon-300x300.jpg 300w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/ramon-150x150.jpg 150w\" sizes=\"auto, (max-width: 313px) 100vw, 313px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-left\">Ram\u00f3n Re\u00f1\u00e9<\/h2>\n\n\n\n<p>Asesor m\u00e9dico<br>CO-FUNDADOR<\/p>\n\n\n\n<ul class=\"wp-block-social-links is-layout-flex wp-block-social-links-is-layout-flex\"><\/ul>\n<\/div>\n<\/div>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-columns col-reverse is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<h2 class=\"wp-block-heading\">Lidia Casas<\/h2>\n\n\n\n<h4 class=\"wp-block-heading\">Asesora de Protecci\u00f3n Intelectual<\/h4>\n\n\n\n<p>L\u00eddia es agente de patentes europeas (EQE-2014) y es licenciada en Bioqu\u00edmica. Se dedica profesionalmente al mundo de la propiedad industrial-intelectual desde hace 19 a\u00f1os, especialmente en los campos de biotecnolog\u00eda, biomedicina y medtech. Cre\u00f3 su propio proyecto de consultor\u00eda en patentes particularmente para empresas start-up. L\u00eddia trabaja para ADmit Therapeutics como IP Manager externa, gestionando todos los aspectos de IP de la empresa.<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-top is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:33.33%\">\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"313\" height=\"313\" src=\"https:\/\/admit:8890\/wp-content\/uploads\/2024\/11\/lidia.jpg\" alt=\"\" class=\"wp-image-144\" srcset=\"https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/lidia.jpg 313w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/lidia-300x300.jpg 300w, https:\/\/admit-therapeutics.com\/wp-content\/uploads\/2024\/11\/lidia-150x150.jpg 150w\" sizes=\"auto, (max-width: 313px) 100vw, 313px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-left\">Lidia Casas<\/h2>\n\n\n\n<p>Asesora de Protecci\u00f3n Intelectual<\/p>\n\n\n\n<ul class=\"wp-block-social-links is-layout-flex wp-block-social-links-is-layout-flex\"><li class=\"wp-social-link wp-social-link-linkedin  wp-block-social-link\"><a href=\"https:\/\/www.linkedin.com\/in\/l%C3%ADdia-casas-i-sanahuja-8237651\/\" class=\"wp-block-social-link-anchor\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" version=\"1.1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" aria-hidden=\"true\" focusable=\"false\"><path d=\"M19.7,3H4.3C3.582,3,3,3.582,3,4.3v15.4C3,20.418,3.582,21,4.3,21h15.4c0.718,0,1.3-0.582,1.3-1.3V4.3 C21,3.582,20.418,3,19.7,3z M8.339,18.338H5.667v-8.59h2.672V18.338z M7.004,8.574c-0.857,0-1.549-0.694-1.549-1.548 c0-0.855,0.691-1.548,1.549-1.548c0.854,0,1.547,0.694,1.547,1.548C8.551,7.881,7.858,8.574,7.004,8.574z M18.339,18.338h-2.669 v-4.177c0-0.996-0.017-2.278-1.387-2.278c-1.389,0-1.601,1.086-1.601,2.206v4.249h-2.667v-8.59h2.559v1.174h0.037 c0.356-0.675,1.227-1.387,2.526-1.387c2.703,0,3.203,1.779,3.203,4.092V18.338z\"><\/path><\/svg><span class=\"wp-block-social-link-label screen-reader-text\">LinkedIn<\/span><\/a><\/li><\/ul>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Equipo Ferran Prat Presidente del Consejo de Administraci\u00f3n Ferran Prat Presidente del Consejo de Administraci\u00f3n \u00c9l cuenta con m\u00e1s de 30 a\u00f1os de experiencia en la industria de Ciencias de la Vida, principalmente en Diagn\u00f3stico y Farma. Ha ocupado cargos como CEO, Vicepresidente Corporativo de Marketing, Alianzas Estrat\u00e9gicas y Desarrollo de Negocio, as\u00ed como Director [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":3,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-135","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/admit-therapeutics.com\/es\/wp-json\/wp\/v2\/pages\/135","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admit-therapeutics.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/admit-therapeutics.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/admit-therapeutics.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/admit-therapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=135"}],"version-history":[{"count":26,"href":"https:\/\/admit-therapeutics.com\/es\/wp-json\/wp\/v2\/pages\/135\/revisions"}],"predecessor-version":[{"id":646,"href":"https:\/\/admit-therapeutics.com\/es\/wp-json\/wp\/v2\/pages\/135\/revisions\/646"}],"wp:attachment":[{"href":"https:\/\/admit-therapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=135"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}